Ms. Tracey Lynn Thomas, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 1017 Main Street, Pocahontas, IL 62275 Phone: 618-541-8410 Fax: 618-651-0433 |
News Archive
A gene mutation associated with a rare sleep disorder surprisingly also contributes to debilitating migraines, a new discovery that could change the treatment of migraines by allowing development of drugs specifically designed to treat the chronic headaches.
TearLab Corporation announced today that, further to its press release of October 8, 2010, a unique new Current Procedural Terminology code that will apply to the TearLab Osmolarity test has now been published by the American Medical Association. The new code will become effective January 1, 2011.
Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended September 30, 2011 (3Q11) of $2.67, compared to $2.32 per share for the quarter ended September 30, 2010.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
In New York, state medical centers and drug makers have begun an effort to address a problem associated with clinical drug trials: "getting patients to sign up. More than 3,000 clinical trials are actively recruiting in New York state, and an additional 8,000 trials involving New York are already running or were recently completed, according to the government clinical trials registry. Patient recruitment is one of the top reasons that clinical trials are delayed or fail, according to the Tufts Center for the Study of Drug Development.
› Verified 8 days ago